Trials / Terminated
TerminatedNCT03408652
Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
Multicenter Randomized Phase III Study Evaluating the Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Centre Leon Berard · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, randomized, open-label, 2-arm, parallel-group, phase III study whose goal is to assess the efficacy and safety profile of bone-targeted treatments (Arm A: denosumab or zoledronic acid) versus the control arm (Arm B: no specific treatment) in patients with bone metastases under targeted therapy for Metastatic Renal Cell Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | denosumab | Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use. |
Timeline
- Start date
- 2019-03-15
- Primary completion
- 2020-06-22
- Completion
- 2020-06-22
- First posted
- 2018-01-24
- Last updated
- 2021-10-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03408652. Inclusion in this directory is not an endorsement.